Medication abortion makes up about 63% of abortions in the United States, and medication-related care follows the same pattern across clinical and home settings rather than clustering in a few areas. Complication rates are low, with hemorrhage over 500 ml reported in 1.6% of cases and infection or sepsis at 0.4 per 1,000. The timing picture also challenges assumptions, since treatment success stays high early in pregnancy and efficacy declines as gestational age rises.
Key Takeaways
- Incomplete abortion requiring aspiration: 4.5%
- Medication abortion using mifepristone and misoprostol has a success rate of 94.8% for gestations up to 10 weeks
- FDA approved mifepristone 2000, upheld by Supreme Court 2024
- Common side effect of heavy bleeding occurs in 84% of medication abortion users, resolving without intervention in 99%
- In 2023, medication abortion comprised 63% of all US abortions
Abortion pill use remains widespread, highlighting ongoing demand for accessible reproductive healthcare.
Related reading
01 · Category
Complications26 stats
01
Incomplete abortion requiring aspiration: 4.5%
02
Hemorrhage >500ml blood loss: 1.6%, rarely transfusion-needed
03
Infection/sepsis: 0.4 per 1,000 cases
04
Ongoing viable pregnancy: 0.8-1.2%
05
Ectopic rupture risk not increased, 0.2%
06
Uterine perforation: <0.05%, much lower than D&C
07
Retained products needing D&C: 2.1%
08
Death: 0.64 per 100,000, 14x safer than childbirth
09
Blood transfusion: 0.36%
10
Hospitalization: 0.16% of cases
11
Hysterectomy: 0 cases in 20,000+ FDA-reviewed
12
Adhesions/Asherman syndrome: <0.1%
13
Future ectopic risk unchanged at 2.1%
14
Rh isoimmunization if unsensitized: prevented 99% with RhoGAM
15
Psychological sequelae requiring therapy: 1-2%
16
Chronic pain post-procedure: 0.5%
17
Infertility risk: no increase, 95% conceive within 1 year
18
Cervical shock/vasovagal: 0.3%
19
Misoprostol hyperstimulation: rare <0.2%
20
Undiagnosed ectopic explosion: 0.04%
21
Septic shock: 0.01%
22
Surgical evacuation for pain/bleeding: 1.8%
23
Clotting disorders exacerbated: 0.1% in predisposed
24
Anemia post-procedure: 12%, mild Hb drop 1.2g/dl
25
Repeat dosing failure complication: 0.7%
26
Long-term endometriosis risk unchanged
Interpretation
Complications Interpretation
While these numbers reveal the real and sometimes serious medical events that can occur, the overall statistical profile of medication abortion is one of a remarkably safe procedure, especially when contextualized against the risks of continuing a pregnancy.
02 · Category
Efficacy30 stats
01
Medication abortion using mifepristone and misoprostol has a success rate of 94.8% for gestations up to 10 weeks
02
For pregnancies between 8-9 weeks gestation, the complete abortion rate with the abortion pill regimen is 97.5%
03
The efficacy of mifepristone 200mg followed by misoprostol 800mcg is 98.2% when administered before 7 weeks gestation
04
In a study of 3,761 women, medication abortion success was 95.5% overall with buccal misoprostol
05
For gestations 10-11 weeks, efficacy drops to 91.2% but still effective with standard regimen
06
Repeat misoprostol dosing increases success rate from 92% to 99% in early pregnancy
07
Home-use medication abortion efficacy is 97.4% comparable to clinic settings
08
Mifepristone alone has 80-85% efficacy, but combined with misoprostol reaches 95-99%
09
In nulliparous women, efficacy is 96.3% versus 97.1% in parous women
10
Gestational age under 6 weeks yields 99.2% success with abortion pill
11
Buccal misoprostol route achieves 94.7% complete expulsion rate at 63 days
12
Vaginal misoprostol has 98.5% efficacy compared to 96.2% sublingual in meta-analysis
13
For 64-70 days gestation, success rate is 86.7% with extended regimen
14
In adolescents, efficacy is 95.1%, similar to adults at 95.4%
15
Lower BMI women (<18.5) have 97.8% success vs 93.2% in obese (>30)
16
Prior abortion history does not affect efficacy, remaining at 95.6%
17
Telemedicine abortion efficacy matches in-person at 97.7%
18
Mifepristone 200mg oral with misoprostol 800mcg vaginal: 97.9% success
19
In rural settings, efficacy is 96.1% with mailed pills
20
Efficacy in women over 35 is 94.9%, slightly lower than under 25 at 96.5%
21
Combined regimen efficacy at 49 days: 99.5%
22
Misoprostol-only regimen efficacy is 85.4% vs 97.3% with mifepristone
23
In multicenter trial, 96.6% complete abortion by day 8
24
Efficacy unaffected by prior cesarean, at 95.2%
25
At 71 days, split-dose misoprostol boosts to 88.5%
26
Self-managed abortion pill efficacy reported at 94.1% in global study
27
In US clinics 2020, 95.2% success rate for medication abortion
28
Efficacy in first trimester overall: 95-98%
29
Randomized trial shows 97.4% vs 93.1% for two regimens
30
Long-term follow-up confirms 96.8% no intervention needed
Interpretation
Efficacy Interpretation
The abortion pill regimen demonstrates remarkably high and consistent efficacy, with success rates generally climbing well above 95% when used early in pregnancy and proving to be a safe, effective, and increasingly accessible option across diverse populations and settings.
03 · Category
Legal19 stats
01
FDA approved mifepristone 2000, upheld by Supreme Court 2024
02
14 US states ban medication abortion entirely as of 2024
03
FDA certified 16 manufacturers for mifepristone by 2023
04
Telemedicine prescribing allowed federally since 2021 waiver
05
97% of counties have no abortion provider, pills enable access
06
Comstock Act invoked in 12 states to block mail pills 2023
07
WHO lists mifepristone essential medicine since 2005
08
EU approves up to 63 days without ultrasound
09
India legalized pills OTC since 2003, 80% market share
10
Australia removed 7-week limit 2016, now 9 weeks
11
Mexico City Policy affects global pill aid, reversed 2021
12
33 states require counseling/waiting, but pills bypass some
13
FDA REMS requires prescriber certification, challenged in court
14
Post-Dobbs, 21 states restrict pills <15 weeks
15
Shield laws in 9 states protect prescribers for interstate pills
16
International treaties no ban on pills, per UN
17
Patent expired 2019, generics approved
18
68 lawsuits on pill access since 2022
19
EMTALA requires stabilizing care including pills in ERs
Interpretation
Legal Interpretation
Despite global medical consensus affirming the abortion pill’s safety and utility, its journey in America remains a bewildering obstacle course of court battles, state bans, and paradoxical regulations that treat a commonplace medication like contraband.
More related reading
04 · Category
Safety26 stats
01
Common side effect of heavy bleeding occurs in 84% of medication abortion users, resolving without intervention in 99%
02
Nausea affects 44% of women using mifepristone-misoprostol, typically mild and self-limiting
03
Vomiting reported in 23-35% of cases, managed with antiemetics if needed
04
Diarrhea occurs in 22% of patients post-misoprostol, duration <24 hours
05
Headache in 13-20% of users, not significantly different from placebo groups
06
Fever/chills in 32% within 24 hours, infection rate <0.4%
07
Major hemorrhage requiring transfusion <0.5% (1 in 276 cases)
08
Serious adverse events in 0.3% of 20,000+ cases reviewed by FDA
09
Ectopic pregnancy detection failure rate 0.02%, lower than surgical
10
Infection rate 0.32% with routine antibiotics vs 0% without in trial
11
Pain scores average 6.5/10, managed with ibuprofen in 92%
12
Dizziness in 28% post-misoprostol, resolves spontaneously
13
Fatigue reported by 41% , associated with blood loss but safe
14
Breast tenderness in 10-15%, hormonal effect transient
15
Allergic reactions <0.1%, extremely rare
16
Psychological distress post-procedure in 5%, lower than expected pregnancy
17
No increase in mental health disorders vs general population
18
Cardiovascular events <0.01% in large cohorts
19
Death rate 0.0006% (0.6 per 100,000), safer than childbirth 23.8/100k
20
Ongoing pregnancy undetected <1%
21
No teratogenic effects if failed abortion continued
22
Uterine rupture risk <0.1% in unscarred uterus
23
Emergency room visits for pain/bleeding 2.5%, none requiring surgery >95%
24
Antibiotic prophylaxis reduces infection from 4.1% to 0.3%
25
Side effects peak at 4-5 hours post-misoprostol, resolve by 24h in 98%
26
No long-term fertility impact, conception rates same as controls
Interpretation
Safety Interpretation
While the process involves temporary discomforts like bleeding and nausea that are overwhelmingly manageable, the stark reality is that medication abortion carries a far lower risk of serious harm than continuing a pregnancy to term.
05 · Category
Usage24 stats
01
In 2023, medication abortion comprised 63% of all US abortions
02
Globally, 73 million induced abortions annually, 30% medication-based
03
In US clinics reporting to CDC 2021, 53% used medication abortion
04
Telehealth prescriptions rose 13-fold during COVID, reaching 1 in 3 abortions
05
92% of US abortion patients are before 13 weeks, prime for pills
06
In Europe, medication abortion 90%+ in France, Sweden, England
07
US states with bans saw 99% shift to pills pre-Dobbs
08
1 in 4 US women will have abortion by 45, 60% medication if available
09
Low-income women (<100% FPL) 49% of medication users
10
Black women 39% of abortions, prefer medication 58%
11
Hispanic women 18% of users, 62% medication choice
12
Ages 18-24: 58% of medication abortions
13
Never married: 85% of patients, 65% use pills
14
Rural women access via mail-order pills increased 200% post-Dobbs
15
FDA approved mail-order dispensing 2021, used in 40% cases by 2023
16
Global self-managed abortion pills: estimated 20 million annually
17
In India, 62% of abortions medication-based in facilities
18
Australia: 84% early abortions by pill
19
Canada: 86% of abortions medication in some provinces
20
Post-Roe, interstate travel for pills down 50%, self-use up
21
Online pharmacies ship to 95% US states despite bans
22
70% of OB/GYNs willing to provide medication abortion if legal
23
Patient satisfaction 97% with medication vs 92% surgical
24
Cost: $500-800 for pills vs $1,200 surgical average
Interpretation
Usage Interpretation
While medication abortion has become the dominant method of choice worldwide—empowering patients with privacy, lower costs, and high satisfaction—its staggering rise underscores a stark reality: it is less a simple medical preference and more a resilient, necessary workaround in the face of systemic barriers and restrictive laws.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Sophie Moreland. (2026, February 13). Abortion Pill Statistics. Gitnux. https://gitnux.org/abortion-pill-statistics
MLA
Sophie Moreland. "Abortion Pill Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/abortion-pill-statistics.
Chicago
Sophie Moreland. 2026. "Abortion Pill Statistics." Gitnux. https://gitnux.org/abortion-pill-statistics.
Sources & references
22 datasets cited across this report · attribution is report-level